Compare Mesoblast Limited (MESO) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Paychex, Inc. — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Paychex, Inc. trades at $112.68 (market cap $40.98B). The key difference: Paychex, Inc. is far larger — about 18.9× Mesoblast Limited's market cap, and Paychex, Inc. pays a 4.13% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | PAYX | |
|---|---|---|
Market Cap | $2.17B | $40.98B |
Sector | Technology | Industrials |
52-Week High | $20.96 | $147.99 |
52-Week Low | $12.88 | $85.57 |
Enterprise Value | $2.17B | $44.47B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Paychex (PAYX) trades at $115.15, up 0.66% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 beating expectations of $1.31, and maintains high profitability with a 27.03% net income margin. Recent developments include dividend declarations and positive small business job growth trends.
Outlook remains positive with steady revenue growth and AI expansion driving future performance, though valuation metrics appear elevated with P/E at 23.39. Key risks include macroeconomic sensitivity to small business hiring and competitive pressures. Analyst consensus is mixed with 63.33% hold ratings and a $110 price target slightly below current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
